Skip to main content

Joan López Hellin

Soc facultatiu especialista del Servei de Bioquímica, on soc responsable de la plataforma de cromatografia i espectrometria de masses i de l'anàlisi d'elements traça. Soc membre del grup de recerca de Bioquímica Clínica del Vall d'Hebron Institut de Recerca (VHIR).

Institutions of which they are part

Senior researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Bioquímic/a Clínic/a
Bioquímica
Cross-departmental services

Joan López Hellin

Institutions of which they are part

Senior researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Bioquímic/a Clínic/a
Bioquímica
Cross-departmental services

Soc facultatiu especialista del Servei de Bioquímica, on soc responsable de la plataforma de cromatografia i espectrometria de masses i de l'anàlisi d'elements traça. Soc membre del grup de recerca de Bioquímica Clínica del Vall d'Hebron Institut de Recerca (VHIR).

Em vaig llicenciar en Química per la Universitat de Barcelona (1982) i vaig fer la meva tesina al CSIC (1985). Vaig fer la residència de Bioquímica Clínica a l'Hospital Vall d'Hebron (1988), on treballo des de 1989. Em vaig doctorar en Medicina per la Universitat Autònoma de Barcelona l'any 2000. Des dels anys 90 em vaig especialitzar en anàlisis per espectrometria de masses, enfocant els meus interessos de recerca en la descoberta de nous biomarcadors per proteòmica dirigida en malalties renals. La meva activitat assistencial actual comprèn la mesura d'elements traça per espectrometria de masses amb plasma acoblat inductivament i la gestió de la plataforma d'espectrometria de masses, inclòs el desenvolupament de mètodes d'anàlisi basats en proteòmica quantitativa.

Research lines

Focal segmental glomerulosclerosis

Idiopathic nonfamilial focal segmental glomerulosclerosis (FSG) is a disease with no treatment, whose usual outcome is end-stage renal disease frequently recidivating after transplantation. In close cooperation with the Nephrology and Paediatric Nephrology services of  Vall d'Hebron hospital together with hospitals throughout the country that provide a significant number of patients, we intend to identify the hypothetical blood factor that causes the proteinuria observed in this disease. Identification of such plasma factor, by means of differential proteomic analysis, would allow the definition of therapeutic targets for the disease, which currently lacks an effective treatment. Our second objective is to find biomarkers that enable us to foresee a potential recidivation and the consequent loss of the graft following renal transplantation to FSG patients.

IP: Joan López Hellin

Técnicas diagnósticas amb Targeted proteomics

IP: Joan López Hellin, Yolanda Villena Ortiz

Desenvolupament i optimització de mètodes diagnòstics

IP: Joan López Hellin

Projects

RED NACIONAL DE LABORATORIOS DE FUNCION RENAL

IP: Francesc Moreso Mateos
Collaborators: Gema Ariceta Iraola, Joan López Hellin
Funding agency: Instituto de Salud Carlos III
Funding: 42900
Reference: PMP22/00119
Duration: 01/01/2023 - 31/12/2025

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Collaborators: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Perez Dueñas, Belen, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Ariadna Boloix Amenós, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Cazurro Gutierrez, Ana Laura, Gómez Andrés, David, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Bou Teen, Diana, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala
Funding agency: Instituto de Salud Carlos III
Funding: 2494527.53
Reference: FORT23/00034
Duration: 01/01/2024 - 31/12/2027

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: Ibane Abasolo Olaortua
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Francisco Rodríguez Frias, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Rosanna Paciucci Barzanti, Zamira Vanessa Diaz Riascos, Marc Miquel Moltó Abad, Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Beatriz Pacín Ruíz, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Incorporació Dr. Daniel Serón a la RETICS en Malalties renals

IP: Daniel Serón Micas
Collaborators: Gema Ariceta Iraola, Joan López Hellin, Anna Meseguer Navarro, Ramón Vilalta Casas, Francesc Moreso Mateos, Enric Trilla Herrera, Natalia Ramos Terrades, David Lorente García, Maria Jose Soler Romeo, Meritxell Ibernon Vilaró, Joana Sellarés Roig, María Eugenia Espinel Garuz, Luis Enrique Lara Moctezuma, Irene Agraz Pamplona, Marina Muñoz López, Irina Betsabe Torres Rodriguez, Luis Augusto Castro Sáder, Manel Perelló Carrascosa
Funding agency: Instituto de Salud Carlos III
Funding: 102300
Reference: RD16/0009/0030
Duration: 01/01/2017 - 31/12/2021

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Verónica Villagrasa Araya

Verónica Villagrasa Araya

Predoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Irene Corrales  Insa

Irene Corrales Insa

Main researcher
Transfusional Medicine
Read more
Albert Vilanova Baldellou

Albert Vilanova Baldellou

Shock, Organ Dysfunction and Resuscitation
Read more
David Espejo Castellanos

David Espejo Castellanos

Predoctoral researcher
Pneumology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.